Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage —…
Continue Reading-
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1…
Continue Reading -
Helsestartups får stryk på mangfold, e24.no
Helsestartups får stryk på mangfold, e24.no — Hadean Ventures Home Portfolio Team Impact Investors News…
Continue Reading -
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal — Hadean Ventures Home…
Continue Reading -
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan —…
Continue Reading -
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study…
Continue Reading -
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial — Hadean…
Continue Reading -
Galecto Announces Pricing of Initial Public Offering
Galecto Announces Pricing of Initial Public Offering — Hadean Ventures Home Portfolio Team Impact Investors…
Continue Reading -
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli® — Hadean Ventures Home Portfolio…
Continue Reading -
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study — Hadean Ventures…
Continue Reading